Drugs in ATC Class M01AC

Up to Top Level ATC Classes

Up to M - Musculo-skeletal system

Up to M01 - ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

Up to M01A - ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS

Drugs in ATC Class: M01AC - Oxicams

Tradename	Generic Name
FELDENE	piroxicam
PIROXICAM	piroxicam
ZYNRELEF KIT	bupivacaine; meloxicam

Market dynamics and patent landscape for ATC Class M01AC (Oxicams): exclusivity timelines, Orange Book status, and generic entry risk

Last updated: June 18, 2026

ATC Class M01AC (oxicams) includes prescription NSAIDs such as meloxicam and piroxicam (and in some coding schemas also tenoxicam). In the US, the market’s near-to-mid-term dynamics are driven by (1) the age of core active-ingredient IP estates, (2) remaining formulation and method-of-use patent pockets that can delay label expansions or switch-to-generic timing, and (3) the strength of FDA listing footprints (Orange Book entries) for specific NDA/ANDAs. Patent enforcement and Paragraph IV outcomes tend to hinge on whether remaining patents are tied to a current listed strength, dosage form, or dosing regimen rather than to the base API.

No complete, jurisdiction-wide patent/Orange Book dataset for the entire M01AC subclass can be produced from the information provided in this prompt alone.

What patents protect oxicams (ATC M01AC) like meloxicam and piroxicam in the US?

Short answer (US): Oxicam IP protection is typically concentrated in formulation (e.g., tablet composition, dissolution profile, coatings, particle size), manufacturing (process claims), and method-of-use (dose-ranging, administration schedules) rather than in first-generation polymorph-only claims. For older oxicams, many “core” composition claims have already expired or are no longer commercially relevant, shifting the remaining risk to secondary patents listed in the Orange Book for specific approved products.

Which oxicam molecules fall under M01AC in commercial practice?

• Meloxicam (widely used; multiple dosage forms in the US).
• Piroxicam (older product; fewer current US-centric product permutations than meloxicam).
• Other oxicams sometimes seen in ATC practice (for example tenoxicam) depending on classification usage by payer systems, country reference lists, and EHR coding.

How is the patent estate usually structured for oxicams?

1. Base compound and early composition
   Often expired for older oxicams by now, leaving limited leverage unless a product-specific bridge remains (e.g., a new salt, hydrate, or polymorph).
2. Formulation and controlled-release
   Tablet excipient systems, coating technologies, and dissolution/release rate adjustments are the most common sources of remaining enforceable patents for NSAIDs.
3. Manufacturing and process
   Granulation conditions, compression parameters, drying conditions, and particle-size control can generate late-expiring patents that are tied to a specific NDA strength.
4. Method-of-use and dosing regimen
   Label-anchored method claims can be asserted against “same use” generics when the generic seeks FDA approval for the same indication and dosage.

When does oxicams exclusivity end and when do patents expire for meloxicam and piroxicam?

Short answer: For mature oxicams, useful exclusivity windows are mostly gone for the underlying API. The gating items now are (1) unexpired Orange Book-listed patents attached to each NDA for each dosage form/strength, and (2) whether the generic challenges (Paragraph IV) target those specific patents.

Exclusivity vs patents: what matters to market timing?

• Patent expiration controls hard IP barriers.
• Regulatory exclusivity can delay generic approval even after patent expiration, but for long-marketed oxicams it is often limited to niche label changes or newer formulations.

Practical timing drivers for generic entry

• Generic applicants time filings around:
  • the next unexpired listed patent,
  • whether they can omit patent challenges using “non-infringing” carveouts,
  • and whether they can secure an approval date that bypasses “listed drug” blocking issues.

Key market implication

For oxicams, generic entry risk is rarely “first-day API loss.” It is about the last remaining listed patents for the currently marketed formulation/strength and whether those patents are:

• method-of-use (possible generic “carveout”),
• formulation (often difficult to design around without changing release profile),
• or manufacturing (harder to assess without discovery).

What is the Orange Book status of meloxicam and piroxicam products, and how many listed patents remain?

Short answer: Orange Book status is product- and strength-specific. In oxicams, the “how many patents remain” question is only answerable product-by-product because one NDA can have a short list while another has more formulation/method entries tied to different dosage forms.

How Orange Book listings affect competitive landscape

• A generic filing for a listed drug typically must either:
  • certify to each patent (Paragraph I-IV), or
  • seek approval via a pathway that avoids blocking patents.
• The number of listed patents plus their claim type determines:
  • likelihood of a Paragraph IV suit,
  • probability of settlement terms that delay entry,
  • and whether a court’s construction narrows practical enforcement.

Data requirement issue

A complete answer needs current Orange Book listings for each relevant NDA/strength and then mapping each listed patent to expiration and claimed scope. The prompt does not include those listings.

How strong is the patent estate for oxicams: formulation, method-of-use, and manufacturing barriers

Short answer: For oxicams, the patent estate strength in 2025 to 2028 is usually concentrated in secondary patents. Strength varies by:

• whether claims cover a marketed formulation (composition and release),
• whether claims were challenged in prior Paragraph IV cases,
• and whether the assignee/patentee has a history of enforcing remaining claims.

Formulation patents: the typical holdback

• Shell/cap structure, binder systems, disintegration agents, coating compositions.
• Release specifications can limit “easy swaps” to generic formulations.

Method-of-use: label leverage

• Claims tied to dosing schedules (for example once-daily vs divided dosing) can create litigation leverage when a generic seeks the same indication and schedule.

Manufacturing patents: harder-to-design-around

• Process claims can delay generic approvals indirectly via patent infringement allegations, though generic applicants may still avoid infringement by using different steps.
• Court outcomes hinge on claim construction and evidence of process equivalence.

Which companies are challenging oxicam patents with Paragraph IV ANDAs, and what settlements shape generic entry?

Short answer: Paragraph IV litigation for oxicams typically involves brand-side assignees and generics targeting the most economically relevant strengths. Settlement outcomes often trade:

• a defined “carveout” entry date,
• a narrow label scope for the generic,
• and sometimes market-sharing, channel agreements, or licensing terms.

What determines whether Paragraph IV cases settle

• Whether the asserted patents are likely to be upheld at claim construction.
• Whether the generic product design can plausibly avoid infringement.
• Whether market value is concentrated in a few strengths that both sides care about.

Data requirement issue

A specific list of challengers, case numbers, and settlement terms requires named litigants and docket-level information, which is not provided in the prompt.

What generic entry risks exist for meloxicam and piroxicam: FDA approval timing, design-around, and label carveouts?

Short answer: The biggest risks to generic entrants in oxicams are:

1. Listed patent breadth over formulation and dissolution profile,
2. Method-of-use claims that block approvals for the full label,
3. Settlement-driven delayed launch even when patents appear weak.

Design-around risk profile by claim type

• Formulation: high risk unless the generic can hit release and composition requirements without crossing claimed features.
• Method-of-use: medium to high risk if the generic’s label matches the claimed regimen; label carveouts can mitigate but may reduce market.
• Manufacturing: medium risk; depends on whether the generic’s process materially differs and whether the court views process equivalence broadly.

What investors watch

• Patent expiry calendar for the NDA(s) that own the strongest commercial positions.
• Status of ongoing injunctions, appeals, and post-judgment enforcement.

How does meloxicam compare with piroxicam on patent lifecycle and generic availability?

Short answer: Meloxicam is generally more commercially developed with a larger footprint of product variations and thus often a larger set of Orange Book entries over time. Piroxicam is typically older and less dynamically contested in modern FDA commercialization cycles. Patent risk for both tends to be dominated by secondary patents tied to specific formulation and dosing.

Competitive dynamic implication

• Meloxicam tends to have more “product granularity” and therefore more ways to carve around or to litigate around particular strengths.
• Piroxicam tends to have fewer modern formulation options; litigation is more likely to concentrate on fewer products, so each listed patent can have outsized effect.

Which jurisdictions matter for oxicam patent enforcement beyond the US?

Short answer: For oxicams, US patents drive much of generic entry timing through Hatch-Waxman. In parallel, enforcement and validity challenges abroad matter for:

• market access outside the US,
• manufacturing and distribution,
• and negotiating leverage for global licensing or settlement structures.

Typical jurisdiction set

• EU member states and the UK for SPC-anchored and formulation-driven claims.
• Canada for market entry timing (data exclusivity and PM(NOC) litigation).
• Other high-volume generics markets where patent linkage or launch timing frameworks exist.

Data requirement issue

A jurisdiction-by-jurisdiction patent landscape needs a jurisdictional patent family map that is not supplied.

What formulations of oxicams are protected by patents: tablets, capsules, oral suspensions, and topical alternatives?

Short answer: For oxicams marketed in the US, patents most often cover oral solid forms. If topical oxicam formulations exist in a given jurisdiction, the patent risk shifts to:

• permeability enhancers,
• viscosity and vehicle systems,
• and stability.

Key formulation categories that attract IP

• Immediate-release tablets
• Once-daily formulations (where present)
• Orally dissolving or specialty tablet technologies (where present)
• Fixed combinations (if any specific products exist in the relevant markets)

Why formulation matters economically

Oxicam commercial strategy is often strength- and dose-indexed. A generic can reduce infringement risk by targeting different strengths or avoiding certain release profiles, but payers and formularies may still create demand for the flagship strengths.

What FDA regulatory milestones influence patent strategy for oxicams?

Short answer: Oxicam IP strategy tracks FDA milestones:

• NDA approvals and supplements for new formulation/strengths,
• ANDA submissions and paragraph certifications,
• labeling changes that can reshape method-of-use and indication coverage.

Regulatory timing levers

• Citizen petitions or REMS-like mechanisms are less common for NSAIDs but labeling and approval pathway decisions can move entry timing.
• Patent listing updates (and Orange Book maintenance) can shift the set of blocking patents for later generics.

Data requirement issue

FDA milestone timelines by drug and NDA are not included in the prompt.

What patent litigation affects oxicam markets: injunctions, claim construction, and appeal outcomes?

Short answer: In oxicams, the market impact of litigation comes from:

• injunctions tied to specific strengths,
• claim construction narrowing that determines whether a generic’s design avoids infringement,
• and settlement agreements that define launch dates and label scope.

What usually moves the needle in court

• Whether the asserted claims are specific enough to be infringed by the generic’s formulation/process.
• Whether the patentee can prove infringement with the evidence available at the infringement stage.
• Validity arguments (prior art, obviousness, enablement), especially for secondary patents.

Data requirement issue

Specific case lists, docket dates, and outcomes cannot be produced from the prompt.

Revenue exposure: which oxicam products carry the highest post-patent risk for brand erosion?

Short answer: Revenue exposure concentrates in the oxicam products that still have:

• meaningful market share,
• and unexpired Orange Book-listed patents for their flagship strengths/dosage forms.

How to translate patent status into revenue risk

• Identify the branded product with the highest sales within M01AC.
• Map remaining unexpired patents per NDA/strength.
• Measure the probability of generic entry based on:
  • litigation status,
  • settlement likelihood,
  • and whether unchallenged patents remain.

Data requirement issue

No product-level revenue or current market share inputs are provided.

Key Takeaways

• Oxicams in ATC M01AC are mature NSAIDs; market timing is now driven by secondary formulation/method/manufacturing patents and Orange Book listings by NDA, strength, and dosage form, not by base API compound protection.
• Generic entry risk is product-specific and usually hinges on whether remaining patents are listed and claim-broad over the exact generic target.
• Paragraph IV litigation and settlements determine practical launch timing more than theoretical patent strength alone.
• A definitive “how many patents remain, when they expire, who is suing, and what entry dates result” requires up-to-date Orange Book and litigation dockets for each relevant NDA strength within M01AC; that dataset is not present in the prompt.

FAQs

1. Which oxicams in ATC M01AC are most likely to still have Orange Book-listed patents that block generic entry?
2. How do formulation patents for once-daily oxicams change generic design-around strategies?
3. What’s the typical litigation pattern for NSAID secondary patents: formulation first, method-of-use second, or vice versa?
4. How often do oxicam Paragraph IV cases resolve via settlement that delays launch through agreed entry dates?
5. What label carveout strategies do generic applicants use for method-of-use patents covering dosing schedules?

References

1. FDA, “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration.
2. FDA, “Hatch-Waxman: Patent Certifications (Paragraph I-IV).” U.S. Food and Drug Administration.